Verrica Pharmaceuticals Inc (NASDAQ:VRCA) currently has a daily average trading volume of 404.80K but it saw 374284 shares traded in last market. With a market cap of 45.02M USD, the company’s current market price of $0.49 came rising about 2.36 while comparing to the previous closing price of $0.48. In past 52 weeks, the stock remained buoying in the range of price level as high as $11.41 and as low as $0.38. In the recent trading on the day, stock has struck highest price mark of $0.4369 while lowest mark touched by it was $0.4905.
Taking a look at 20-day trading activity of Verrica Pharmaceuticals Inc (VRCA) gives us an average price of $0.4875, while its current price level is -95.70% below from 52-week high level whereas it is 28.54% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.5875 while that of 200 days or SMA-200 reads an average of $1.9794. A closer look into the stock’s movement over the week reveals that its volatility is standing at 15.28% during that period while stretching the period over a month that increases to 18.42%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 46.67 which implies that the stock is in neutral territory.
Needham issued its recommendations for the stock as it upgraded the price target for the stock is $10.
Over the week, VRCA’s stock price is moving 10.82% up while it is -20.95% when we observe its performance for the past one month. Year-to-date it is -29.93% down and over the past year, the stock is showing a downside performance of -92.99%.
The company is expected to be releasing its next quarterly report on 2025-Mar-10, for which analysts forecasted an EPS of -0.14 while estimate for next year EPS is -0.43. In next quarter, company is expected to be making quarterly sales of $3.53M as analysts are expecting the sales for current fiscal year at $16.25M and seeing the company making $31.75M in sales next year. Moreover, analysts are in estimates of $2.53M for current-quarter revenue.
Currently, Verrica Pharmaceuticals Inc’s total number of outstanding shares is 91.78M. Company’s return on investment (ROI) stands at -340.74% and return on equity (ROE) at -1546.58%. Stock’s beta reads 1.63. Stock has a price to sale or P/S ratio amounts to 5.95. Its return on asset (ROA) is -112.44% on average.
